2021323
PR Heartseed Initiates Ph1/2 Clinical Trial of iPSC-derived Cardiomyocyte Spheroids (LAPiS Study) in Japan
202131
PR Heartseed named "Minister of Science and Technology Policy Award" at Japan Venture Awards 2021
2021128
Other Taiji Edogawa was appointed as External Audit & Supervisory Board Member
20201130
PR Heartseed Named "Healthcare Company of the Year 2020" by Healthcare Insights Magazine
2020915
Other Mutsuki Takano was appointed as Chief Financial Officer (CFO)
202062
Other Takehiko Kaneko was appointed as Chief Medical Officer (CMO)
2020310
PR Announced Capital and Business Alliance with MEDIPAL HOLDINGS
PR Announced Capital Alliance with ITOCHU CHEMICAL FRONTIER
2020130
Other Kay Deguchi was appointed as Independent Director
2020129
Media Links of Keiichi Fukuda' interviews were posted at CEO Message.
